Aethlon Medical, Inc. (OQ:AEMD)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 11555 Sorrento Valley Road, Suite 203
SAN DIEGO CA 92121
Tel: N/A
Website: https://www.aethlonmedical.com
IR: See website
<
Key People
James B. Frakes
Interim Chief Executive Officer, Chief Financial Officer, Senior Vice President - Finance, Company Secretary, Director
Guy F. Cipriani
Chief Operating Officer, Senior Vice President
Lee D. Arnold
Chief Scientific Officer
Steven P. Larosa
Chief Medical Officer
   
Business Overview
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
Financial Overview
For the nine months ended 31 December 2023, Aethlon Medical, Inc. revenues was not reported. Net loss increased 2% to $9.8M. Higher net loss reflects Payroll and related expenses increase of 33% to $4.2M (expense), Professional Fees increase of 8% to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.39 to -$3.95.
Employees: 15 as of Mar 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.57M as of Dec 31, 2023
EBITDA (TTM): -$12.28M as of Dec 31, 2023
Net annual income (TTM): -$12.26M as of Dec 31, 2023
Free cash flow (TTM): -$10.77M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 2,620,399 as of Feb 9, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.